Disproportional response: a small company's current business is visibly outgrowing its own size
The model's full reasoning — Q2 2018 call → NOWe need to determine if management conveys that the business is visibly outgrowing the company's own size. The transcript shows management discussing strong growth, new products, capacity constraints, and strategic investments. They mention that they are forgoing potential revenue due to supply constraints, and that the Chongqing JV will provide capacity for additional annual revenue of ~$150M. They also mention digital power as a growth initiative. However, the question asks if the current business is disproportionately large relative to the company's smallness. Management does not explicitly state that the company is small and that current demand is huge relative to that. They talk about growth and capacity constraints, but that's typical of a growing company. They don't contrast the size of the company with the scale of what's arriving. They mention "tens of millions of dollars" of forgone revenue due to capacity constraints, but that's not necessarily disproportionate. The company's revenue is ~$100M per quarter, so tens of millions annually is significant but not necessarily "disproportionately large." They also talk about the JV supporting $150M additional annual revenue, which is large relative to current revenue, but that's future capacity, not current business. The question asks about "current activity, demand, or commitments arriving at a scale that is large relative to how small the company still is." Management does mention that they are experiencing supply constraints and forgoing revenue, which implies demand exceeds capacity, but they don't frame it as "we are small and this is huge." They also mention that the digital power team is being built, but that's future. The overall tone is positive growth, but not a clear statement of disproportion. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
VNRX · Q1 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management explicitly describing the Heska deal (already signed and with $10M upfront received) as a long-term, multi-year commitment that will generate ongoing kit/component revenue "significantly greater" than the $28M milestones, with "millions of tests" expected each year — all while repeatedly noting the company is "not a big company" and that this is "the beginning of our commercial journey" after 12 years of R&D. They contrast this with their tiny current revenue ($114k) and cash position, framing the new activity as disproportionately large relative to their size.
TMCI · Q2 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES Management explicitly describes the business as outgrowing its current setup in present-tense terms: they are “once again in the process of relocating to a larger headquarters facility” to meet “increased requirements” for training, R&D, warehousing, and infrastructure; the direct sales force has grown 52% to 123 quota-carrying reps and is already trending above the year-end 70% direct mix goal; surgeon penetration has reached 20% of the estimated 10,000 U.S. foot-and-ankle surgeons while procedure penetration is 4.6% of the 450,000 annual U.S.
KOPN · Q4 2023 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management describing current activity (a $55 million backlog, a $20.5 million new order, follow-on orders, and tripled weapon-site volume expected in 2024) as large relative to the company’s still-small size and setup. They explicitly note the backlog is a “record level 10 years,” that they had to extend the holiday shutdown and retool the plant for a “significant increase in production,” and that they are “buying to that level of volume today” while remaining conservative on guidance.